Apriori Bio
MA - CambridgeBiotechnology
Focus: Apriori Bio is an AI-driven biotech platform company focused on viral variant identification, headquartered in Cambridge, MA and founded in 2020. The company operates in the pre-clinical/platform stage with active hiring suggesting early-stage scaling.
Profile data last refreshed 52m ago · AI intelligence enriched 1w ago
Open Jobs
85+40 this month
Hot — 71 jobs added in 30d
Net +40 (71 new, 31 removed). Aggressive expansion phase.
Should You Work at Apriori Bio?
AI assessmentStrong fit for AI/biotech specialists seeking equity upside and early-stage impact; poor fit for those prioritizing near-term clinical catalysts or financial transparency.
Why Work Here
- Ground-floor opportunity at an early-stage AI biotech founded in 2020 with strong R&D focus (24 of 75 roles in R&D)
- Emerging platform in viral variant identification positions you at intersection of AI and oncology, a high-growth sector
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Apriori Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.